A prospective study of serum 25-hydroxyvitamin D levels and mortality among African Americans and Non-African Americans

American Journal of Epidemiology

Volumn 177, Issue 2, 2013, Pages 171-179

  Signorello, Lisa B ^a,b,c   Han, Xijing ^a   Cai, Qiuyin ^b,c   Cohen, Sarah S ^a   Cope, Elizabeth L ^a   Zheng, Wei ^b,c   Blot, William J ^a,b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

African Americans; biological markers; cardiovascular diseases; mortality; neoplasms; prospective studies; vitamin D; vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D;

AFRICAN AMERICAN; BIOMARKER; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; DISEASE PREVALENCE; HEALTH RISK; MORTALITY; PARTICIPATORY APPROACH; PUBLIC HEALTH; SERUM; VITAMIN DEFICIENCY;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD SAMPLING; FEMALE; HUMAN; MALE; MORTALITY; PREVALENCE; VITAMIN D DEFICIENCY;

ADULT; AFRICAN AMERICANS; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; SEASONS; SOUTHEASTERN UNITED STATES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84872250245     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws348     Document Type: Article

References (59)

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-281.
2. Chadha MK, Tian L, Mashtare T, et al. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer. 2010;116(9):2132-2139.
3. Laverny G, Penna G, Vetrano S, et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett. 2010;131(1):49-58.
4. Penna G, Amuchastegui S, Laverny G, et al. Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells. J Bone Miner Res. 2007;22(suppl 2):V69-V73.
5. Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J Pharmacol. 2009;158(2):395-412.
6. Walsh JE, Clark AM, Day TA, et al. Use of α,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol. 2010;71(7):659-665.
7. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006; 96(2):252-261.
8. Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J Pharmacol. 2009;158(2):395-412.
9. Boucher BJ. Vitamin D insufficiency and diabetes risks. Curr Drug Targets. 2011;12(1):61-87.
10. Bikle DD. Vitamin D regulation of immune function. Vitam Horm. 2011;86:1-21. (doi:10.1016/B978-0-12-386960-9.00001-0).
11. Melamed ML, Michos ED, Post W, et al. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629-1637.
12. Ginde AA, Scragg R, Schwartz RS, et al. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc. 2009;57(9):1595-1603.
13. Hutchinson MS, Grimnes G, Joakimsen RM, et al. Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Tromso Study. Eur J Endocrinol. 2010;162(5):935-942.
14. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340-1349.
15. Pilz S, Dobnig H, Nijpels G, et al. Vitamin D and mortality in older men and women. Clin Endocrinol. 2009;71(5): 666-672.
16. Kuroda T, Shiraki M, Tanaka S, et al. Contributions of 25-hydroxyvitamin D, co-morbidities and bone mass to mortality in Japanese postmenopausal women. Bone. 2009;44(1): 168-172.
17. Semba RD, Houston DK, Bandinelli S, et al. Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. Eur J Clin Nutr. 2010;64(2):203-209.
18. Michaelsson K, Baron JA, Snellman G, et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010;92(4): 841-848.
19. Johansson H, Oden A, Kanis J, et al. Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden. Osteoporos Int. 2012;23(3):991-999.
20. Eaton CB, Young A, Allison MA, et al. Prospective association of vitamin D concentrations with mortality in postmenopausal women: results from the Women's Health Initiative (WHI). Am J Clin Nutr. 2011;94(6): 1471-1478.
21. Cawthon PM, Parimi N, Barrett-Connor E, et al. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. J Clin Endocrinol Metab. 2010;95(10): 4625-4634.
22. Minino AM. Death in the United States, 2009. NCHS data brief, no. 64. Hyattsville, MD: National Center for Health Statistics; 2011.
23. Signorello LB, Hargreaves MK, Blot WJ. The Southern Community Cohort Study: investigating health disparities. J Health Care Poor Underserved. 2010;21(1 suppl): 26S-37S.
24. Ersfeld DL, Rao DS, Body JJ, et al. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem. 2004;37(10):867-874.
25. Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem. 2009;42(15):1549-1556.
26. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press; 2010.
27. Vieth R, Bischoff-Ferrari H, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr. 2007;85(3):649-650.
28. Lee P, Eisman JA, Center JR. Vitamin D deficiency in critically ill patients. N Engl J Med. 2009;360(18): 1912-1914.
29. Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26(18): 2984-2991.
30. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004-1013.
31. Matthews LR, Ahmed Y, Wilson KL, et al. Worsening severity of vitamin D deficiency is associated with increased length of stay, surgical intensive care unit cost, and mortality rate in surgical intensive care unit patients. Am J Surg. 2012;204(1):37-43.
32. Braun AB, Gibbons FK, Litonjua AA, et al. Low serum 25-hydroxyvitamin D at critical care initiation is associated with increased mortality. Crit Care Med. 2012;40(1):63-72.
33. Zittermann A, Iodice S, Pilz S, et al. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr. 2012;95(1): 91-100.
34. Looker AC, Johnson CL, Lacher DA, et al. Vitamin D Status: United States, 2001-2006. NCHS data brief, no. 59. Hyattsville, MD: National Center for Health Statistics; 2011.
35. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167(16):1730-1737.
36. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr. 2008;88(6): 1519-1527.
37. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84(1):18-28.
38. Freedman DM, Looker AC, Abnet CC, et al. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res. 2010;70(21):8587-8597.
39. Pilz S, Dobnig H, Winklhofer-Roob B, et al. Low serum levels of 25-hydroxyvitamin D predict fatal cancer in patients referred to coronary angiography. Cancer Epidemiol Biomarkers Prev. 2008;17(5):1228-1233.
40. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double-blind controlled trial. BMJ. 2003; 326(7387):469. (doi:10.1136/bmj.326.7387.469).
41. Brunner RL, Wactawski-Wende J, Caan BJ, et al. The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr Cancer. 2011;63(6): 827-841.
42. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care. 2008;11(1): 7-12.
43. Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest. 1991;87(6):1889-1895.
44. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279(34):35798-35802.
45. Wu-Wong JR, Nakane M, Ma J, et al. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis. 2006;186(1): 20-28.
46. Wu-Wong JR, Nakane M, Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res. 2007;44(1):11-18.
47. Bucharles S, Barberato SH, Stinghen AE, et al. Hypovitaminosis D is associated with systemic inflammation and concentric myocardial geometric pattern in hemodialysis patients with low iPTH levels. Nephron Clin Pract. 2011; 118(4):c384-c391.
48. Jablonski KL, Chonchol M, Pierce GL, et al. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011;57(1): 63-69.
49. Li YC, Qiao G, Uskokovic M, et al. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89-90:387-392. (doi.org/10.1016/j.jsbmb.2004.03.004).
50. Krause R, Buhring M, Hopfenmuller W, et al. Ultraviolet B and blood pressure. Lancet. 1998;352(9):709-710.
51. Judd SE, Raiser SN, Kumari M, et al. 1,25 Dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: a pilot feasibility study. J Steroid Biochem Mol Biol. 2010; 121(1-2):445-447.
52. Al Mheid I, Patel R, Murrow J, et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol. 2011;58(6):186-192.
53. Giovannucci E, Liu Y, Hollis BW, et al. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168(11):1174-1180.
54. Kilkkinen A, Knekt P, Aro A, et al. Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol. 2009;170(8):1032-1039.
55. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963-968.
56. Wang L, Manson JE, Song Y, et al. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010;152(5): 315-323.
57. Sonderman JS, Munro HM, Blot WJ, et al. Reproducibility of serum 25-hydroxyvitamin D and vitamin D-binding protein levels over time in a prospective cohort study of black and white adults. Am J Epidemiol. 2012;176(7):615-621.
58. Hofmann JN, Yu K, Horst RL, et al. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2010;19(4):927-931.
59. Kotsopoulos J, Tworoger SS, Campos H, et al. Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev. 2010; 19(4):938-946.